Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma

BACKGROUND: Although epidermal growth factor receptor (EGFR) and its truncated, autoactive mutant EGFR variant (v)III are bona fide drivers of tumorigenesis in some gliomas, therapeutic antibodies developed to neutralize this axis have not improved patient survival in a limited number of trials. Pre...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Greenall, Sameer A, McKenzie, Mathew, Seminova, Ekatarina, Dolezal, Olan, Pearce, Lesley, Bentley, John, Kuchibhotla, Mani, Chen, Shengnan C, McDonald, Kerrie L, Kornblum, Harley I, Endersby, Raelene, Adams, Timothy E, Johns, Terrance G
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2019
主題:
Basic and Translational Investigations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6682217/
https://ncbi.nlm.nih.gov/pubmed/31002307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz073
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料